wbradfordweller200fBradford Weller, JD

Chief Executive Officer and General Counsel

Brad Weller is an accomplished and driven c-level executive with over 20 years of experience providing legal leadership, oversight, and guidance within technology, software, and bio-science industries. He is a result-oriented leader with diverse and complex transactional experience, buiding strategic and business planning.

He has demonstrated an ability to minimize risks of legal liability and ensure maximum legal rights of the company. Adept with international transactions, including contracting, cross-border mergers and acquisitions (M&A), and employment. He has extensive corporate governance expertise, and is skilled in working with boards of directors, audit committees, and executive compensation committees. He has a track record of successful resolution of commercial, M&A, employement, and IP infringment/protection disputes.

Read more ...


Dennis Wright, PhD

Chief Chemistry Officer

Professor of Medicinal Chemistry
University of Connecticut, Storrs

Management of QMD research portfolio

Dr. Wright's research program lies at the interface of organic structure and biological function, and is grounded in a strong synthetic organic core that also includes many important aspects of modern medicinal chemistry, including structure-based drug design, drug disposition/metabolism, and high-throughput screening. He leads a successful research group at the UConn School of Pharmacy, with 18 years continuous research support, including over $10 million in funding, six awarded patents and over 100 peer-reviewed publications, and has trained over 20 doctoral students and several post-doctoral fellows.

Read more ...

weller200fSandra K. Weller, PhD

Chief Biology Officer

Board of Trustees Distinguished Professor and Chair    2003 - present
Department of Molecular Biology and Biophysics
University of Connecticut School of Medicine, Farmington

Management of QMD research portfilio.

Dr. Weller has broad experience in molecular genetics, biochemistry and cell biology, with a focus on identifying molecular targets relevant to disease. Her considerable experience in multidisciplinary research development includes promotion of academic translational drug discovery efforts.

She has established a highly successful research group in molecular virology and virus-host interactions at the University of Connecticut School of Medicine, with 32 years of continuous research support totaling over $13 million in state, industry and federal support, and has one patent granted and over 100 peer-reviewed publications.

Her energetic style and collaborative leadership abilities have earned her international respect. She has led efforts to integrate strengths in clinical medicine, bioinformatics, molecular biology, biochemistry, biophysics, structural biology and medicinal chemistry to enable new discoveries in the clinical and basic sciences. This effort resulted in a $10 million state funded partnership between the University of Connecticut and Yale University, known as the Program in Innovative Therapeutics for CT's Health, or PITCH, which aims to translate basic science discoveries into therapeutic strategies that can be used to promote human health.  

Read more ...

LeeWright200aLee Wright, PhD

VP, Research and Discovery

Dr. Wright has over 17 years of pharma experience, including early stage drug development and refinement and preclinical studies. He has extensive experience in synthetic chemistry, medium and large-scale synthesis, and impurity profiling, SAR modeling, and metabolite analysis. In addition, he has CRO / management experience with PD-ADME studies, and modeling of safety / toxicology and animal efficacy.

He has contributed to the development of Roxadustat, currently in Phase III for the treatment of anemia and chronic kidney disease.

Read more ...